drugset
drugset / Trial / NCT06542497

Evaluate Efficacy and Safety of POS to Improve Distance-corrected Near Visual in Participants With Presbyopia

NCT06542497 ↗

Phase 3 Completed 569 enrolled Ocuphire Pharma, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

Safety and efficacy of POS in participants with presbyopia

Timeline

Start
2024-08-15
Primary completion
2025-04-03
Completion
2026-01-22

Drugs

EvaluationDrugModalityDoseRoute
Comparator Phentolamine Small molecule 0.75 % —

Indications

presbyopia